毛霉病
医学
疾病
免疫抑制
大流行
重症监护医学
中性粒细胞减少症
流行病学
传染病(医学专业)
免疫学
2019年冠状病毒病(COVID-19)
病理
内科学
毒性
作者
Ishita Gupta,Pritika Baranwal,Gagandeep Singh,Vandana Gupta
标识
DOI:10.2217/fmb-2022-0141
摘要
Mucormycosis is an emerging opportunistic angioinvasive fungal infection. Predisposing factors such as diabetes, neutropenia, long-term corticosteroid therapy, solid organ transplantation and immunosuppression contribute to its occurrence. This disease was not of significant concern prior to the COVID-19 pandemic, but gained prominence due to infections in COVID-19 patients. Mucormycosis needs special attention and coordinated efforts of the scientific community and medical professionals to reduce morbidity and mortality. Here we present an overview of the epidemiology and prevalence of mucormycosis in the pre- and post-COVID-19 eras, the factors that contributed to the abrupt increase in COVID-19-associated mucormycosis (CAM), the actions taken by the regulatory agencies (including Code Mucor and CAM registry), the existing diagnostic tools and CAM management strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI